Radiation treatment outcomes for unresectable hepatocellular carcinoma

LAUR Repository

Show simple item record

dc.contributor.author Skinner, Heath
dc.contributor.author Sharp, Hadley
dc.contributor.author Kaseb, Ahmed
dc.contributor.author Javle, Milind
dc.contributor.author Vauthey, Jean-Nicolas
dc.contributor.author Abdalla, Eddie
dc.contributor.author Declos, Marc
dc.contributor.author Das, Prajnan
dc.contributor.author Crane, Christopher
dc.contributor.author Krishnan, Sunil
dc.date.accessioned 2015-11-20T08:59:02Z
dc.date.available 2015-11-20T08:59:02Z
dc.date.copyright 2011
dc.date.issued 2015-11-20
dc.identifier.issn 0393-7542 en_US
dc.identifier.uri http://hdl.handle.net/10725/2644
dc.description.abstract Background. Hepatocellular carcinoma is one of the most common cancers worldwide. Data regarding the use of radiotherapy is limited in patients from populations without endemic viral hepatitis. We examine the outcomes for patients treated with radiotherapy in the modern era at a single institution. Material and methods. A total of 29 patients with localized hepatocellular carcinoma treated from 2000–2010 were reviewed. Patients with metastatic disease at the time of radiation were excluded. Median radiation dose was 50 Gy (range 30 to 75 Gy) with a median biologically effective dose of 80.6 (range 60 to 138.6). Median tumor size at the time of radiation was 5.2 cm (range 2 to 25 cm). Results. Eighty three percent of all patients had either stable disease or a partial response to radiation, based on RECIST criteria. Median change in tumor size following radiation was −17% (range −73.5 to 177.8%). Estimated one-year overall survival and in-field progression-free survival rates for the study population were 56% and 79%, respectively. One-year overall survival in patients treated to a biologically effective dose <75 was significantly lower than in patients treated to a biologically effective dose ≥75 (18% vs. 69%). One-year in-field progression-free survival rate (60% vs. 88%) and biochemical progression-free survival duration (median 6.5 vs. 1.6 months) were also significantly improved in patients treated to a biologically effective dose ≥75. Grade 3 toxicity was seen in 13.8% of patients. Discussion. In a population without endemic viral hepatitis, unresectable hepatocellular carcinoma demonstrates significant response to radiotherapy with minimal toxicity. Furthermore, our findings suggest that increased biologically effective dose is associated with improved survival and local tumor control. en_US
dc.language.iso en en_US
dc.title Radiation treatment outcomes for unresectable hepatocellular carcinoma en_US
dc.type Article en_US
dc.description.version Published en_US
dc.author.school SOM en_US
dc.author.idnumber 201100945 en_US
dc.author.woa N/A en_US
dc.author.department N/A en_US
dc.description.embargo N/A en_US
dc.relation.journal Acta Oncologica en_US
dc.journal.volume 50 en_US
dc.journal.issue 8 en_US
dc.article.pages 1191-1198 en_US
dc.identifier.doi http://dx.doi.org/10.3109/0284186X.2011.592147 en_US
dc.identifier.ctation Skinner, H. D., Sharp, H. J., Kaseb, A. O., Javle, M. M., Vauthey, J. N., Abdalla, E. K., ... & Krishnan, S. (2011). Radiation treatment outcomes for unresectable hepatocellular carcinoma. Acta Oncologica, 50(8), 1191-1198. en_US
dc.author.email eddie.abdalla@lau.edu.lb
dc.identifier.url http://www.tandfonline.com/doi/abs/10.3109/0284186X.2011.592147

Files in this item

This item appears in the following Collection(s)

Show simple item record

Search LAUR

Advanced Search


My Account